A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system. We believe this approach has the potential to effectively control diseases with high unmet need that are driven by excessive complement activation. We currently have two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection), approved by the U.S.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 1.0B | 1.0B | 781M | 397M | - | - |
| Net Income | 22M | 22M | -198M | -529M | -652M | -746M |
| EPS | $0.20 | $0.20 | $-1.60 | $-4.45 | $-6.15 | $-8.84 |
| Free Cash Flow | 45M | 45M | -88M | -596M | -515M | -564M |
| ROIC | 7.0% | 8.1% | -45.2% | -192.2% | -61.8% | -156.9% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 2.26 | 2.26 | 3.22 | 0.57 | 0.66 | 1.06 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 55M | 55M | -165M | -517M | -595M | -536M |
| Operating Margin | 5.5% | 5.5% | -21.1% | -130.4% | - | - |
| ROE | 6.0% | 7.5% | -93.5% | -290.1% | -353.9% | -370.2% |
| Shares Outstanding | 112M | 112M | 124M | 119M | 106M | 84M |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 251M | N/A | N/A | 397M | 781M | 1.0B | 1.0B |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 300M | 346M | 387M | 354M | 328M | 296M | 296M |
| SG&A | 139M | 177M | 277M | 501M | 501M | 550M | 550M |
| EBIT | -214M | -536M | -595M | -517M | -165M | 55M | 55M |
| Op. Margin | -85.3% | N/A | N/A | -130.4% | -21.1% | 5.5% | 5.5% |
| Net Income | -345M | -746M | -652M | -529M | -198M | 22M | 22M |
| Net Margin | -137.6% | N/A | N/A | -133.3% | -25.3% | 2.2% | 2.2% |
| Non-Recurring | 0 | 0 | 1.5M | 6.3M | 19M | 21M | 21M |
| Returns on Capital | |||||||
| ROIC | -93.2% | -156.9% | -61.8% | -192.2% | -45.2% | 8.1% | 7.0% |
| ROE | -288.9% | -370.2% | -353.9% | -290.1% | -93.5% | 7.5% | 6.0% |
| ROA | -51.1% | -81.0% | -79.4% | -68.3% | -23.6% | 2.3% | 2.1% |
| Cash Flow | |||||||
| Op. Cash Flow | -160M | -563M | -514M | -595M | -88M | 45M | 45M |
| Free Cash Flow | -166M | -564M | -515M | -596M | -88M | 45M | 45M |
| Owner Earnings | -207M | -635M | -606M | -702M | -204M | -60M | -60M |
| CapEx | 5.4M | 1.1M | 1.5M | 773K | 403K | 313K | 313K |
| Maint. CapEx | 637K | 1.4M | 1.6M | 1.8M | 1.8M | 1.6M | 1.6M |
| Growth CapEx | 4.8M | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 637K | 1.4M | 1.6M | 1.8M | 1.8M | 1.6M | 1.6M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 0.7% | 0.7% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 45M | 71M | 91M | 106M | 114M | 104M | 104M |
| Debt Repayment | 22M | 22M | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | -500M | -490M | -499M | -240M | 325M | 370M | 370M |
| Cash & Equiv. | 566M | 640M | 552M | 351M | 411M | 466M | 466M |
| Long-Term Debt | 359M | 189M | 93M | 93M | 359M | 362M | 362M |
| Debt/Equity | 1.85 | 1.06 | 0.66 | 0.57 | 3.22 | 2.26 | 2.26 |
| Interest Coverage | N/A | N/A | N/A | -90.6 | -4.1 | 1.3 | 1.3 |
| Equity | 205M | 199M | 170M | 195M | 229M | 370M | 370M |
| Total Assets | 961M | 882M | 760M | 789M | 885M | 1.1B | 1.1B |
| Total Liabilities | 756M | 683M | 590M | 594M | 657M | 705M | 705M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -926M | -1.7B | -2.3B | -2.8B | -3.0B | -3.0B | -3.0B |
| Working Capital | 789M | 692M | 552M | 519M | 603M | 691M | 691M |
| Current Assets | 917M | 824M | 720M | 766M | 789M | 1.0B | 1.0B |
| Current Liabilities | 128M | 132M | 168M | 248M | 186M | 324M | 324M |
| Per Share Data | |||||||
| EPS | -4.59 | -8.84 | -6.15 | -4.45 | -1.60 | 0.20 | 0.20 |
| Owner EPS | -2.75 | -7.52 | -5.72 | -5.91 | -1.65 | -0.54 | -0.54 |
| Book Value | 2.72 | 2.35 | 1.60 | 1.64 | 1.85 | 3.31 | 3.31 |
| Cash Flow/Share | -2.14 | -6.67 | -4.84 | -5.01 | -0.71 | 0.40 | 0.21 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 75.1M | 84.4M | 106.0M | 118.8M | 123.7M | 111.9M | 111.9M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | 124.8 | 204.2 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | 62.1 | 101.6 |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | 43.5 | 89.2 |
| Price/Book | 20.6 | 20.1 | 31.0 | 38.4 | 17.7 | 7.6 | 12.4 |
| Price/Sales | 10.4 | N/A | N/A | 17.8 | 7.0 | 2.6 | 4.6 |
| FCF Yield | -3.9% | -14.1% | -9.8% | -8.0% | -2.2% | 1.6% | 1.0% |
| Market Cap | 4.2B | 4.0B | 5.3B | 7.5B | 4.0B | 2.8B | 4.6B |
| Avg. Price | 34.66 | 48.76 | 50.51 | 59.46 | 43.95 | 23.24 | 40.84 |
| Year-End Price | 56.14 | 47.30 | 49.61 | 62.83 | 32.68 | 24.97 | 40.84 |
Apellis Pharmaceuticals, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Apellis Pharmaceuticals, Inc. trades at 204.2x trailing earnings, compared to its 15-year median P/E of 15.0x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 116.0x vs a median of 62.1x.
Apellis Pharmaceuticals, Inc. (APLS) has a current P/E ratio of 204.2, compared to its historical median P/E of 15.0. The stock is currently considered Expensive based on its historical valuation range.
Apellis Pharmaceuticals, Inc. (APLS) has a 5-year average return on invested capital (ROIC) of -89.6%. This is below average and may indicate limited pricing power.
Apellis Pharmaceuticals, Inc. (APLS) has a market capitalization of $4.6B. It is classified as a mid-cap stock.
Apellis Pharmaceuticals, Inc. (APLS) does not currently pay a regular dividend.
Based on historical P/E analysis, Apellis Pharmaceuticals, Inc. (APLS) appears expensive. The current P/E of 204.2 is 1261% above its historical median of 15.0.
Apellis Pharmaceuticals, Inc. (APLS) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Apellis Pharmaceuticals, Inc. (APLS) reported annual revenue of $1.0 billion in its most recent fiscal year, based on SEC EDGAR filings.
Apellis Pharmaceuticals, Inc. (APLS) has a net profit margin of 2.2%. This is a modest margin.
Apellis Pharmaceuticals, Inc. (APLS) generated $45 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Apellis Pharmaceuticals, Inc. (APLS) has a debt-to-equity ratio of 2.26. This indicates higher leverage, which may increase financial risk.
Apellis Pharmaceuticals, Inc. (APLS) reported earnings per share (EPS) of $0.20 in its most recent fiscal year.
Apellis Pharmaceuticals, Inc. (APLS) has a return on equity (ROE) of 7.5%. This indicates moderate shareholder returns.
The Ledger Terminal provides 6 years of financial data for Apellis Pharmaceuticals, Inc. (APLS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Apellis Pharmaceuticals, Inc. (APLS) has a book value per share of $3.31, based on its most recent annual SEC filing.